ScanSource (SCSC) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jul, 2026Executive summary
Accelerated adoption of the hybrid distribution strategy and recent acquisitions are expanding the total addressable market and driving demand, despite a soft environment.
Leadership changes and acquisitions are positioning the company for growth in high-margin, recurring revenue businesses.
Investments in advanced technologies like AI and private 5G, and a focus on partner segmentation, are expected to fuel future growth.
Fiscal year 2024 saw net sales decline 13.9% year-over-year to $3.26 billion, but gross margin improved to 12.2% from 11.9% due to higher Intelisys revenue mix.
Strong cash generation with $371.6 million in operating cash flow and $363.1 million in free cash flow for the year.
Financial highlights
Q4 free cash flow was $53 million, with strong gross profit and Adjusted EBITDA margins.
FY 2024 net sales declined 13.9% year-over-year, and gross profits declined 11%.
GAAP and non-GAAP net income declined 12.5% and 20.5% year-over-year, respectively.
FY 2024 non-GAAP EPS was $3.08, down from $3.85 last year; diluted EPS was $3.06, down from $3.47.
Free cash flow for the year reached $363.1 million, driven by working capital efficiency.
Outlook and guidance
FY 2025 net sales expected between $3.1 billion and $3.5 billion, with Adjusted EBITDA of $140–$160 million.
Adjusted EBITDA margin projected at 4.5%-4.6%.
Free cash flow guidance for FY 2025 is at least $70 million, reflecting completion of major working capital reductions.
Challenging demand environment expected to persist in H1 FY 2025.
Guidance excludes potential impacts from future acquisitions or significant transactions.
Latest events from ScanSource
- Sales rose 30.1%, but margins and earnings fell; FY27 outlook increased.SCSC
Q1 2027 - Board backs all seven nominees, executive compensation, and Deloitte auditor ratification.SCSC
Proxy filing - Growth, MicroAge integration and longer-term executive incentives headline the proxy.SCSC
Proxy filing - Recurring revenue and strategic M&A drive margin expansion and sustainable growth.SCSC
Investor presentation - Strong Q4 and FY results, with MicroAge acquisition set to drive further margin and sales growth.SCSC
Q4 2026 - Recurring revenue and margin expansion drive growth, supported by disciplined capital allocation.SCSC
Investor presentation - Quarterly sales up 8.8% to $766.8M, strong cash flow, margin gains, and new business initiatives.SCSC
Q3 2026 - Recurring revenues and disciplined capital allocation drive margin growth and efficiency.SCSC
47th Annual Raymond James Institutional Investor Conference - Q2 FY26 saw 2.5% sales growth, margin pressure, and reduced full-year guidance.SCSC
Q2 2026